NTRK1 and non-small cell lung carcinoma: For NTRK1/2/3 fusion NSCLC patients, the current preferred first-line therapy is either entrectinib or larotrectinib,320 howbeit the recommendation of larotrectinib is grounded in data from all solid malignancies.